IDH1 and central nervous system cancer: IDH1/2-mutant gliomas and H3K27M midline tumors exemplify this mode, where metabolites such as 2-hydroxyglutarate or global H3K27me3 redistribution repress interferon pathways, chemokines (CXCL9/10), and STING signaling (82–84).